Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2624073
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15
Primary outcome(s): Progression Free Survival
Study Design: Single arm Non-randomized
创建时间：
2012-08-15
